2 Minute Medicine Rewind October 14, 2019
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial 1. Adjuvant FOLFOX ...
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial 1. Adjuvant FOLFOX ...
1. Pelvic and paraaortic lymphadenectomy in advanced ovarian cancer patients provided no overall or progression-free survival benefits compared to patients ...
1. Pelvic and paraaortic lymphadenectomy in advanced ovarian cancer patients provided no overall or progression-free survival benefits compared to patients ...
1. In women with BRCA-associated, newly diagnosed advanced ovarian cancer, olaparib significantly prolonged progression-free survival (PFS) at three years compared to ...
1. In women with BRCA-associated, newly diagnosed advanced ovarian cancer, olaparib significantly prolonged progression-free survival (PFS) at three years compared ...
Worldwide, more than 100 million women use hormonal methods of contraception. Combined oral contraceptives have previously shown an inverse relationship ...
Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial Chagas ...
1. Patients with stage 3 epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) in addition to cytoreductive surgery and ...
1. BRCA1 promoter methylation in normal white blood cells (WBCs) was linked to risk for high-grade serous ovarian cancer (HGSOC). ...
1. Among patients with platinum-sensitive recurrent ovarian cancer, those who received the PARP inhibitor niraparib demonstrated significantly increased progression-free survival ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.